According to data presented at EADV, at week 16 of the phase 2 study, 47.8% to 62.5% of adults receiving tilrekimig achieved EASI 75 across doses, compared with 9.1% to 19.9% with placebo.
|Videos|April 12, 2022
Updated AAD Guidelines to Discuss New Therapies, AD Comorbidities
Author(s)Colleen Hall
Lawrence Eichenfield, MD, of Rady Children's Hospital-San Diego, discusses the American Academy of Dermatology's approach to atopic dermatitis management.
Advertisement
In this video, Lawrence Eichenfield, MD, of Rady Children's Hospital-San Diego, California, discusses the American Academy of Dermatology's approach to atopic dermatitis management.
He was one of the featured speakers at the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference being held from April 9 to 11 in Baltimore, Maryland.
Advertisement
Related to this article
A new report from the National Eczema Association (NEA) found systemic corticosteroids were filled more often than dupilumab, and 13% of Americans live in counties without a dermatology or allergy/immunology practitioner.
Up to 91% of patients reached EASI-75 and up to 67% reached IGA 0/1 at week 152, with no new safety signals, according to Galderma's EADV 2026 data.
Presented as a late breaker at EADV 2026, mid-dose zumilokibart achieved EASI-75 in 65.9% of adults with atopic dermatitis vs 23.4% with placebo at week 16.
EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Remibrutinib for Symptomatic Dermographism
2
Evaluating the Evidence for Emerging Oral Therapies in Psoriasis
3
EADV 2026: HS Assessment and Follow-Up for NPs and PAs
4
Omlyclo, First Interchangeable Xolair Biosimilar, Launches in the US
5